Načítá se...
Structural basis for rifamycin resistance of bacterial RNA polymerase by the three most clinically important RpoB mutations found in Mycobacterium tuberculosis
Since 1967, Rifamaycin (RIF) has been used as a first line antibiotic treatment for tuberculosis (TB), and it remains the cornerstone of current short-term TB treatment. Increased occurrence of RIF-resistant (RIF(R)) TB, ~41% of which results from the RpoB S531L mutation in RNA polymerase (RNAP), ha...
Uloženo v:
| Vydáno v: | Mol Microbiol |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5344776/ https://ncbi.nlm.nih.gov/pubmed/28009073 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/mmi.13606 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|